3 assets in Pelvic Congestion Syndrome

Therapeutic assets addressing Pelvic Congestion Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
4H-1-BENZOPYRAN-4-ONE, 7-((6-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-2,3-DIHYDO-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-, (S)- Pelvic Congestion Syndrome	Pirogov Russian National Research Medical University	P3	B (60)
Micronized Purified Flavonoid Fraction Pelvic Congestion Syndrome	Pirogov Russian National Research Medical University	P3	B (60)
Varinon Pelvic Congestion Syndrome	Pirogov Russian National Research Medical University	P3	B (60)